Laird Norton Wetherby Wealth Management’s Moleculin Biotech MBRX Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4	Closed	-$11K	–	714
2019 Q3	$11K	Hold	4	–	–	﹤0.01%	703
2019 Q2	$13K	Hold	4	–	–	﹤0.01%	680
2019 Q1	$8K	Hold	4	–	–	﹤0.01%	664
2018 Q4	$10K	Sell	4 -5	-56%	-$14.4K	﹤0.01%	633
2018 Q3	$32K	Hold	9	–	–	﹤0.01%	667
2018 Q2	$35K	Hold	9	–	–	﹤0.01%	639
2018 Q1	$36K	Hold	9	–	–	0.01%	639
2017 Q4	$37K	Buy	+9	New	+$38.9K	0.01%	649

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's MBRX Position: Q4 2019 in Review

Laird Norton Wetherby Wealth Management sold out of Moleculin Biotech (MBRX) in Q4 2019, closing a stake of 4 shares — an estimated $11K sold.

Laird Norton Wetherby Wealth Management first reported a position in MBRX in Q4 2017 and held it in 8 quarters. The position peaked at $37K in Q4 2017. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2019.

Laird Norton Wetherby Wealth Management reported no remaining Moleculin Biotech position as of Q4 2019 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 4 Moleculin Biotech shares in Q4 2019, an estimated $11K.
Laird Norton Wetherby Wealth Management first reported a position in Moleculin Biotech in Q4 2017 and held it in 8 quarters.
Laird Norton Wetherby Wealth Management's Moleculin Biotech position peaked at $37K in Q4 2017.
22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2019.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2019, filed 28 Jan 2020.